Alexion Pharmaceuticals, Inc., a biotechnology company, engages in the discovery and development of biologic therapeutic products for the treatment of various diseases in the United States. It develops products for the treatment of hematologic diseases, cancer, and autoimmune disorders. The company’s product pipeline primarily includes Soliris (eculizumab), which is in two Phase III clinical trials, known as TRIUMPH and SHEPHERD for the treatment of paroxysmal nocturnal hemoglobinuria, a blood disorder. Alexion Pharmaceuticals also develops various products that are in pre-clinical research stages, which comprise Soliris (eculizumab) for indications, such as renal transplantation...